{
"info": {
"nct_id": "NCT06312176",
"official_title": "An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer",
"inclusion_criteria": "* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer\n* Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor\n* Is a chemotherapy candidate\n* Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization\n* Has adequate organ function\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Has breast cancer amenable to treatment with curative intent\n* Has experienced an early recurrence (<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment\n* Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications\n* Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease\n* Has an active infection requiring systemic therapy",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer",
"criterions": [
{
"exact_snippets": "unresectable locally advanced or metastatic",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"unresectable locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "centrally-confirmed hormone receptor positive (HR+)",
"criterion": "hormone receptor status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "human epidermal growth factor receptor 2 negative (HER2-)",
"criterion": "HER2 status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "breast cancer",
"criterion": "cancer type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "breast"
}
]
}
]
},
{
"line": "* Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor",
"criterions": [
{
"exact_snippets": "radiographic disease progression",
"criterion": "radiographic disease progression",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "one or more lines of endocrine therapy",
"criterion": "lines of endocrine therapy",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lines"
}
}
]
},
{
"exact_snippets": "unresectable locally advanced/metastatic HR+/HER2- breast cancer",
"criterion": "breast cancer type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "unresectable locally advanced/metastatic HR+/HER2-"
}
]
},
{
"exact_snippets": "one in combination with a CDK4/6 inhibitor",
"criterion": "CDK4/6 inhibitor combination",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Is a chemotherapy candidate",
"criterions": [
{
"exact_snippets": "Is a chemotherapy candidate",
"criterion": "chemotherapy candidacy",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
}
]
},
{
"line": "* Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization",
"criterions": [
{
"exact_snippets": "eastern cooperative oncology group (ECOG) performance status of 0 to 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "assessed within 7 days before randomization",
"criterion": "ECOG performance status assessment timing",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 7 days before randomization"
}
]
}
]
},
{
"line": "* Has adequate organ function",
"criterions": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy",
"criterions": [
{
"exact_snippets": "Human immunodeficiency virus (HIV)-infected participants",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "well controlled HIV on antiretroviral therapy",
"criterion": "HIV control",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "well controlled"
}
]
},
{
"exact_snippets": "antiretroviral therapy",
"criterion": "antiretroviral therapy",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": true
}
]
}
]
},
{
"line": "* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load",
"criterions": [
{
"exact_snippets": "Hepatitis B surface antigen (HBsAg) positive",
"criterion": "Hepatitis B surface antigen (HBsAg)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "received HBV antiviral therapy for at least 4 weeks",
"criterion": "HBV antiviral therapy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "undetectable HBV viral load",
"criterion": "HBV viral load",
"requirements": [
{
"requirement_type": "detectability",
"expected_value": false
}
]
}
]
},
{
"line": "* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable",
"criterions": [
{
"exact_snippets": "history of Hepatitis C virus (HCV) infection",
"criterion": "Hepatitis C virus (HCV) infection",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "HCV viral load is undetectable",
"criterion": "HCV viral load",
"requirements": [
{
"requirement_type": "detectability",
"expected_value": "undetectable"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Has breast cancer amenable to treatment with curative intent",
"criterions": [
{
"exact_snippets": "breast cancer",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "amenable to treatment with curative intent",
"criterion": "treatment intent",
"requirements": [
{
"requirement_type": "intent",
"expected_value": "curative"
}
]
}
]
},
{
"line": "* Has experienced an early recurrence (<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment",
"criterions": [
{
"exact_snippets": "Has experienced an early recurrence (<6 months after completing adjuvant/neoadjuvant chemotherapy)",
"criterion": "early recurrence",
"requirements": [
{
"requirement_type": "time since chemotherapy",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "therefore is eligible to receive second-line (2L) treatment",
"criterion": "eligibility for second-line treatment",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
}
]
},
{
"line": "* Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications",
"criterions": [
{
"exact_snippets": "Has symptomatic advanced/metastatic visceral spread",
"criterion": "visceral spread",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
},
{
"requirement_type": "stage",
"expected_value": "advanced/metastatic"
}
]
},
{
"exact_snippets": "at risk of rapidly evolving into life-threatening complications",
"criterion": "risk of life-threatening complications",
"requirements": [
{
"requirement_type": "risk level",
"expected_value": "rapidly evolving"
}
]
}
]
},
{
"line": "* Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer",
"criterions": [
{
"exact_snippets": "Has received prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "unresectable locally advanced or metastatic breast cancer",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"unresectable locally advanced",
"metastatic"
]
}
]
}
]
},
{
"line": "* Active autoimmune disease that has required systemic treatment in the past 2 years",
"criterions": [
{
"exact_snippets": "Active autoimmune disease",
"criterion": "autoimmune disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
},
{
"exact_snippets": "required systemic treatment in the past 2 years",
"criterion": "systemic treatment for autoimmune disease",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "years"
}
}
]
}
]
},
{
"line": "* History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease",
"criterions": [
{
"exact_snippets": "History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids",
"criterion": "history of noninfectious pneumonitis/interstitial lung disease",
"requirements": [
{
"requirement_type": "treatment requirement",
"expected_value": "steroids"
}
]
},
{
"exact_snippets": "current pneumonitis/interstitial lung disease",
"criterion": "current pneumonitis/interstitial lung disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has an active infection requiring systemic therapy",
"criterions": [
{
"exact_snippets": "active infection requiring systemic therapy",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "systemic therapy"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}